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Abstract
African trypanosomes express a glycosylphosphatidyl inositol (GPI)-anchored variant-specific surface glycoprotein (VSG) as a protective
coat. During infection, large amounts of VSG molecules are released into the circulation. Their interaction with various cells of the immune
system underlies the severe infection-associated pathology. Recent results have shown that anti-GPI vaccination can prevent the occurrence
of this pathology. © 2002 Éditions scientifiques et médicales Elsevier SAS. All rights reserved.
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1. Introduction
African trypanosomes are protozoan parasites that cause
disease in man and livestock. Among the large variety of
trypanosome species found, only two species, i.e. Trypano-
soma rhodesiense and T. gambiense, are infectious to man.
These parasites are distributed throughout numerous subSa-
haran countries and cause human sleeping sickness, a
deadly disease against which the human immune system is
unable to mount a protective response. Annually, about
300,000 individuals are estimated to attract trypanosomosis,
while more than 50 million people are believed to be
continuously exposed to the danger caused by T. rhod-
esiense and T. gambiense parasites. Although none of the
other trypanosome species present in Africa cause a direct
risk for humans, livestock infections can have indirect
devastating effects on public health. Indeed, because of the
infections in cattle, pigs, sheep, and goats by parasites such
as T. congolense and T. evansi, a major problem at the level
of protein availability for man occurs in regions where the
tsetse fly (Glossina genus) or other hematophagic flies can
serve as parasite vectors. For example, the presence of the
Glossina vector alone already makes at least 10 million
square kilometers of potential African grazing land unsuit-
able for livestock breeding, and places at least one-third of
the African cattle herd at risk of trypanosomosis. Due to this
vast geographic distribution of the disease vector, and the
large number of potential vertebrate hosts which can carry
different trypanosome species, complete eradication of try-
panosomosis is a virtually impossible mission. With regard
to the control and eradication of human sleeping sickness, a
number of drug treatments have been developed in order to
cure ongoing infections. A severe problem that occurs here
is that most of the drugs used, especially those that serve as
treatment during the neuropathological late stage of the
infection, show significant toxicity. As such, the treatment in
itself can be lethal in a considerable percentage of patients.
Moreover, it is clear that drug treatment per se can offer
only a limited solution in regions where trypanosomes are
considered to be endemic. In the end, only the development
of an immune intervention strategy would provide a useful
alternative to a long-lasting total eradication effort. How-
ever, until now, no such strategy has been available due to
the complex life cycle of the trypanosome and its capacity
to continuously evade the host immune system by a mecha-
nism of antigenic variation of its surface coat.
2. African trypanosomes and the immune system
As all African trypanosomes multiply predominantly in
the bloodstream, they need to be able to survive a long-term
exposure to the immune system of their mammalian host.
Hence, coevolution has resulted in the appearance of
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well-balanced growth regulation systems, allowing the para-
site to survive sufficiently long without killing its mamma-
lian host, in order to ensure an effective transmission of the
species. Such a system involves the glycosylphosphatidyl
inositol (GPI)-anchored variant surface glycoprotein (VSG),
which is the major surface antigen and contributes as a
protective coat for the parasite [1]. During the ascending
parasitemia, the majority of the dividing parasites (e.g. long
slender forms) belong to the same antigenic type, called the
homotype, expressing each 107 densely packed identical
VSG molecules on their surface. A peak of parasitemia is
reached when these long slenders differentiate into nondi-
viding short stumpy forms, which have a relatively short in
vivo half-life of 24–36 h, and release VSGs in the circula-
tion upon degeneration [2]. These degenerating parasites not
only allow the host to develop an antibody response to the
homotype, but also confront the immune system with
periodic challenges of vast amounts of parasite-derived GPI
molecules that are now known to be responsible for induc-
tion of inflammatory responses. Together, these events
result in elimination of the major variable antigen type
(VAT), and allow spontaneously arising minor VATs or
heterotypes to continue to multiply, giving rise to a new
peak of parasitemia. Although an effective anti-VSG re-
sponse allows the host to regularly eliminate excessive
numbers of parasites through phagocytosis of opsonized
parasites [3], resistance and survival time of different mouse
strains cannot be directly correlated to the antibody re-
sponse. Indeed, combined results from experimental studies
using different trypanosome strains in both resistant and
susceptible mice as well as their F1 descendants showed
that the ability to produce antibodies to the first variant
antigen population is inherited as a dominant trait, while
survival time during trypanosomosis is inherited as a
recessive trait [4]. Important to keep in mind here is the fact
that experimental rodent infection models do not serve as
good models for human trypanosomosis as concerns the
cause of death. Indeed, while in case of experimental
infection in mice, animals can suffer from high parasitemia
(>108/ml blood) and severe infection-induced anemia dur-
ing the entire course of infection, death itself most often
results from a sudden loss of parasite growth control,
leading to the presence of extremely high numbers of
parasites in the blood and most organs. In contrast, in human
trypanosomosis, the number of parasites present in the
circulation and organs always remain low (<105/ml blood),
and the occurrence of a meningoencephalitis infection stage
leading to coma, rather than uncontrolled parasite growth,
will be the cause of death.
Apart from the analysis of events involved in actual
parasitemia control and control of survival of trypanosome-
infected mammals, it is clear that investigation of the
mechanisms of induction of infection-associated immuno-
pathology is crucial as well. In this context, analysis of the
immunological background of trypanosomosis-associated
immunopathology at the level of cytokine involvement so
far has shown that during T. brucei infections, modulation
of IL-2 and IFN-γ secretion occurs, in combination with the
increased production of the inflammatory cytokines IL-1,
IL-6 and TNF. In man, in particular, the infection-associated
production and systemic presence of TNF is believed to be
related to fever induction and to the severity of
trypanosomosis-induced pathology. Indeed, the presence of
a general state of inflammation in the brain and the
occurrence of the neurological signs during the late-stage
meningoencephalitic phase of the infections are both TNF-
related [5], and the high incidence of mortality, following
anti-trypanosomosis treatment could be TNF-related as well
[6]. In mice, this hypothesis is experimentally supported by
the finding that TNF mRNA in the brain of T. brucei-
infected mice is increased after treatment with anti-
trypanosomal drugs [7]. Further evidence for the detrimen-
tal role of TNF during trypanosome infections comes from
the finding of its involvement in induction of
trypanosomosis-associated immune suppression [8,9] as
well as anemia and cachexia [10]. Finally, it is interesting to
mention here that it was the search for the cachexia-
inducing factor, responsible for the inhibition of lipid
clearance from the blood of T. brucei-infected rabbits,
which gave rise to the isolation of cachectin, later shown to
be identical to TNF [11]. Since the discovery of TNF, it has
become clear that increased TNF production is not a unique
feature of trypanosome infections, but is associated with a
number of other protozoan parasitic diseases as well,
including Chagas’ disease, leishmaniasis, schistosomosis,
and malaria. As such, over the last 15 years, a great effort
has been made to identify the parasite components involved
in TNF induction.
In the case of trypanosomosis, from the start, major
attention in the search for a TNF-inducing component has
been focused on the GPI-linked variant surface glycoprotein
VSG. This molecule represents 10% of the total trypano-
some protein content, and on every peak of infection, the
host is confronted with the release of an enormous quantity
of these molecules [12]. For example, during chronic
infections in mice, parasitemia peaks occur with an interval
of about 7 d, often reaching levels of 107 to 5 × 108
parasites/ml of blood. As parasites are covered with 107
molecules of VSG, and as clearance of these peaks can
occur in as little as 24 h, the immune system is regularly
confronted with the sudden release of up to 4 × 1015
molecules of VSG, or an equivalent of 200 µg of this
parasite compound. Naturally, together with exposure to the
glycoprotein moieties of VSG, the immune system is
confronted with equal molar quantities of parasite-specific
GPI moieties as well.
Before considering the role of the different VSG moieties
in the induction of trypanosomosis-associated pathology, it
is interesting to note that, just as in the case of the discovery
of TNF, it was again through the study of African trypano-
somes that the GPI anchoring method for membrane pro-
teins was discovered [13]. The molecular structure of
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trypanosome GPI was resolved later [14,15], showing the
presence of a trypanosome-specific galactose modification
on the molecule. Based on the VSG C-terminal GPI
processing signal, a VSG classification has been proposed,
placing all VSGs in three separate groups [16]. Interestingly,
the results from the C-terminal classification turned out to
correspond to a second classification system in which the
number of N-linked carbohydrate binding sites served as
selection criteria. In this classification system, group I VSGs
encompass a collection of molecules carrying a single
conserved glycosylation site, about 50 amino acid residues
from the C-terminus [17]. In contrast, group II VSGs have
a first conserved glycosylation site five or six residues from
the C-terminus as well as an additional, second less con-
served glycosylation site [18]. Finally, group III, thus far, is
represented only by one single trypanosome variant, i.e. T.
brucei MITat 1.5. While this VSG variant is characterized
by the presence of three glycosylation sites, it is also unique
in the sense that it is the only VSG described so far that
lacks the trypanosome-specific galactose modification of the
VSG-GPI anchor.
Taking all the data available today, it is clear that the
trypanosome-specific galactose-modified GPI anchor is the
only moiety common to all VSGs, with the exception of the
MIT at 1.5 that shares the GPI core but lacks the galactose
modification. Further, as GPI VSG represents 10% of the
total trypanosome content and as the immune system is
periodically confronted with the presence of vast quantities
of both released VSG and membrane-anchored VSG-GPI
molecules, the trypanosome GPI was a prime target in the
investigation of trypanosomosis-associated pathology and
TNF induction.
3. VSG cleavage from the trypanosome surface occurs
through phospholipase C activation
As described above, VSG molecules are anchored into
the plasma membrane of the trypanosome by means of a
GPI anchor. Surface molecules, anchored via GPI-like
structures are present on all eukaryotic cells. However,
while mammalian cells express up to 105 copies of GPI-like
anchored molecules per cell, parasitic protozoa, including
trypanosomes, express up to 2 × 107 copies of GPI anchor
and/or GPI-related glycolipids per cell [19]. In the case of
trypanosomes, one of the advantages of GPI-type anchors is
the fact that it makes it possible to liberate VSG as a soluble
molecule by means of a phospholipase C (PLC) enzyme,
abundantly present in the parasite [20]. When VSG is
cleaved by a PLC, the dimyristoylglycerol compound
(DMG) of the GPI anchor is left in the membrane while
VSG is released in a soluble form (sVSG) carrying the
glycosyl-inositol-phosphate moiety (GIP) of the GPI. As
PLC-released molecules all have the same distal structure,
this epitope has been called the cross-reacting determinant
or CRD [21]. Polyclonal antibodies against this epitope
have been generated and can be used to discriminate soluble
VSG molecules and membrane bound VSG, independently
of their antigenic type.
Recently it has been shown that during trypanosome
infections, large amounts of sVSG are liberated into the
circulation [12]. Moreover, in living trypanosomes, sVSG is
present in the flagellar pocket [22]. As it is known that PLC
activation in trypanosomes can be induced by different
forms of environmental stress [23], PLC null mutant trypa-
nosomes were generated and used for the study of the
importance of this enzyme activity in parasite development,
virulence, and infection-associated immune modulation.
First, a null mutant was obtained in the T. brucei EATRO
1125 strain. While this parental strain is know to cause an
infection that results in death of the mice after several
weeks, mice infected with the null mutant parasite are
characterized by reduced parasitemia development, reduced
pathology occurrence and prolonged survival [24]. Interest-
ingly, while these parasitemia modifications were observed
in a number of different mouse models (C57Bl/6, BALB/c
and CBA/Ca), they were more recently found to be absent
in C3H/HeN mice that are hypersusceptible to trypanosome
infections and infection-associated pathology. These com-
bined data indicate that while the PLC enzyme itself is
nonessential for parasite survival or VSG switching, the
activation of the trypanosome PLC gene influences specific
host immune responses to the infection. As such, it seems
that the actual cleavage of the VSG-GPI anchor through
PLC activity results in the generation of new parasite
epitope that have a direct influence on the immune activa-
tion stage of the host and result in the induction of
inflammatory responses that are linked to infection-
associated immunopathology. This conclusion is supported
by the recent findings obtained with a second PLC null
mutant parasite that was generated in the hypervirulent 427
T. brucei parasite strain, that fails to be controlled by any
host mediated growth regulation system, and kills infected
mice within 96 h. During this short exponential parasitemia,
no proper induction of any infection controlling specific
host immune response occurs, and as expected, deletion of
the PLC gene from this parasite strain was found to have no
effect on the host mediated control of virulence [25].
Having observed that cleavage of the VSG-GPI anchor
correlates with the induction of an enhanced inflammatory
response during chronic trypanosome infections, the role of
PLC activation on the interaction between trypanosomes
and the immune system has been analyzed in detail. It was
found that attenuation of T. brucei by removal of the PLC
gene is associated with reduced immunosuppression, in-
creased production of Th2 lymphokines, an enhanced IgG1
anti-trypanosome response and the induction of an alterna-
tively activated macrophage population [26,27]. While
these results clearly indicate that the capacity of trypano-
somes to cleave GPI-VSG using PLC activity has a direct
influence on the steering of the infection-associated immune
response, it remains a matter of debate as to how type 1
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versus type 2 responses contribute to the control of experi-
mental trypanosome infections. Indeed, in IL–4-deficient
mice, T. brucei parasitemia control was found to be unal-
tered as compared to wild-type mice [28]. In contrast,
IFN-γ-deficient mice showed drastically reduced survival
when infected with pleomorphic trypanosomes, suggesting
the need for an efficient type-1-mediated immune response
during the early stage of infection [29,30]. Finally, when
IL-10-deficient mice were infected with T. brucei parasites,
the first peak of parasitemia was properly controlled, but
mice succumbed to infection-associated pathology within
2 d of parasite elimination [30]. The latter observation very
closely resembles the findings recorded during the analysis
of T. cruzi infections in IL-10-deficient mice, where, in the
absence of IL-10, mice were found to rapidly succumb due
to a lack of inflammation control resulting in massive TNF
induction and the occurrence of septic shock [31].
Together, it is clear that under environmental or immu-
nological stress conditions, African trypanosomes are ca-
pable of activating an endogenous PLC enzyme that is
responsible for cleavage of the VSG-GPI anchor and release
of sVSG into the circulation. From the currently available
data, it seems that this cleavage results in the generation of
new trypanosome epitopes that are involved in type 1
immune activation, characterized by the production of
increased inflammatory cytokines, including TNF. As such,
it is clear that the analysis of the direct involvement in
macrophage activation of trypanosome GPI and its PLC-
cleaved products, i.e. GIP and DMG, has become crucial for
the understanding of the occurrence of trypanosomosis-
associated immunopathology and inflammation.
4. Two distinct moieties of the VSG-GPI are involved
in the induction of TNF-production, and of infection-
associated LPS hypersensitivity
By the time the first reports were published on the role of
TNF in trypanosome infection [32], it had already been
shown that also in the case of malaria infections, this
cytokine played a crucial role. Moreover, it also had been
proposed by then that the presence of a phosphoinositol-
containing malaria toxin could form the basis for TNF
induction by Plasmodium [33]. Around the same time, a
comparative study of the TNF-inducing capacity of both
Plasmodium- and trypanosome-derived “toxins” showed
that GPI-anchored molecules present in both fractions were
involved in the regulation of TNF expression [34]. As such,
knowing that the GPI-anchored VSG makes up 10% of the
total protein content of the trypanosome, and the fact that at
regular time intervals, huge amounts of soluble VSG are
released into the host blood circulation, this molecule
became a prime target in the investigation of trypano-
somosis-associated TNF induction.
As outlined above, in comparison to mammalian GPI
anchors, the structure of the VSG-GPI is unique in that it
contains a branched galactose side-chain modification [15].
As such, due to the fact that African trypanosomes are
extracellular parasites, releasing vast amounts of soluble
VSG into the circulation during processes of parasite
degradation [3,12], the immune system of an infected
mammalian host is regularly confronted with the presence
of (i) circulating sVSG that carries the galactose-modified
glycosyl-inositol phosphate (GIP) core, and (ii) parasite
membrane fractions that contain the dimyristoylglycerol
(DMG) lipid moiety of the GPI. Although it is clear that
GPI-linked macrophage modulation occurs in all protozoan
parasite infections, this situation is markedly different from
the immune stimulation by, for example, the malaria GPI
toxin or T. cruzi GPI-linked molecules where (i) numbers of
extracellular parasites are several orders of magnitude
lower, (ii) release of vast amounts of soluble cleaved
GIP-linked molecules has not been reported, and (iii) in the
case of malaria GPI, the VSG-specific GIP galactose modi-
fication is absent. As such, when analyzing the TNF-
inducing capacity of trypanosome VSG, the roles of the GIP
and DMG moieties have been studied separately, leading to
the following conclusion [35] (Fig. 1): while trypanosome-
derived galactose-modified GIP is the minimal moiety
needed for the optimal induction of TNF production by
IFN-γ activated macrophages, the presence of excessive
amounts of DMG during chronic trypanosome infections
can lead to macrophage overactivation and induction of LPS
hypersensitivity of the infected host. Given the fact that
accumulation of LPS has been described to occur in the
serum of chronically infected mice [36], these findings
indicate that both GIP and DMG are involved in VSG-
triggered TNF production and trypanosomosis-associated
pathology, respectively, through direct and indirect induc-
Fig. 1. The role of different VSG-GPI moieties in infection-associated
macrophage activation and TNF production during African trypanosomo-
sis. During early stage parasitemia, soluble VSG that carries the GPI
carbohydrate core (sVSG-GIP) is released from the parasite surface and is
involved in the induction of TNF-production by activated macrophages
(Mφ*). During the successive waves of the infection, parasites are killed
and macrophages are confronted with the presence of the lipid moiety of
the VSG-GPI anchor (DMG), that by itself can further activate macropha-
ges and render these cells hypersensitive to LPS stimulation. Due to the
ongoing infection, LPS levels increase in the circulation, causing excessive
TNF production by the sVSG/DMG hyperactivated macrophages (Mφ**),
leading to the occurrence of TNF-mediated trypanosomosis-associated
immunopathology.
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tion pathways. Interestingly, analysis of TNF induction
using a bovine trypanosomosis model has recently con-
firmed the findings presented above. Indeed, in this model,
it was found that sVSG by itself was capable of inducing
TNF production by IFN-γ-primed macrophages in the
absence of the GPI-DMG anchor [37].
When it comes to the signal pathways involved in,
respectively, VSG-GIP and VSG-DMG-triggered macroph-
age activation, all the available information is derived from
experiments in which thyoglicolate-elicited PECs have been
used in combination with MIT at 1.5-derived VSG-GPI
compounds [38,39]. Although the used VSG is character-
ized by the exceptional lack of the VSG-specific galactose
GPI modification, conclusions drawn from the results might
be valid for signals triggered by regular VSGs as well.
Results showed that GIP and DMG trigger two different
signal pathways in macrophages, resulting in the respective
activation of either protein tyrosine kinase or protein kinase
C. Using an in vitro stimulation model, it was furthermore
confirmed that the protein kinase C activation pathway
triggered by DMG could be substituted by IFN-γ activation
[40]. Given the fact that during trypanosome infections
IFN-γ is induced [29], it seems that DMG-mediated macro-
phage activation is only of secondary importance during the
first peaks of infection. This hypothesis is supported by the
finding that in IFN-γ-deficient mice, TNF induction as well
as TNF-associated signs of pathology are significantly
reduced during trypanosome infections, not withstanding
the fact that parasitemia levels themselves are increased and
as such, both the amounts of released VSG-GIP and DMG
are increased as well [30].
The fact that TNF itself is a key mediator in trypano-
somosis-associated immunopathology has long been sug-
gested and has been confirmed using TNF-deficient mice
[9]. As concerns trypanosome components involved in the
induction of TNF, it seems clear from the data described
above that the galactose-modified GIP moiety present on
released soluble VSG is a key factor. However, in the
context of the TNF induction potential of factors derived
from other protozoan parasites, the intrinsic activity of VSG
has been questioned. Indeed, when the in vitro TNF
induction capacity of sVSG is compared to the activity of
GPI mucins from intracellular T. cruzi parasites, it is clear
that its activity is at least 100- to 1000-fold lower [41].
However, when considered in a physiological context (i.e.
in vivo), this might not be surprising. In the case of
trypomastigote-derived GPI mucin, the optimal concentra-
tion for inducing TNF production was found to be in the
1–10 nM range, corresponding to physiological parasite
loads in vivo. Optimal in vitro TNF induction by VSG, on
the other hand, is obtained in the low µM range. Taking into
account the fact that, during an ongoing trypanosome
infection in mice, up to 200 µg of VSG can be released into
the circulation within 24 h, the observed dose response can
be considered as physiologically relevant as well.
One important feature of GPI-triggered TNF induction
that is seen in T. brucei-triggered TNF induction as well as
plasmodium- and T. cruzi-triggered TNF induction is the
fact that a parasite-specific carbohydrate modification at the
level of the GIP core seems to be crucial for optimal
activation. Indeed, while for sVSG, the presence of a
trypanosome-specific galactose modification is required for
optimal activity, GPIs from plasmodium require the pres-
ence of a distal fourth mannose residue [42]. When TNF
induction by the highly potent T. cruzi tGPI mucin is
considered, it is interesting to note that, in this case, both a
distal fourth mannose residue as well as a GIP-linked
galactose modification are present [43].
Finally, as to the question through which surface inter-
action parasite-derived GPI-anchored molecules initiate sig-
nal transduction in activated macrophages, the answer is
still awaiting full elucidation. While in the case of Plasmo-
dium GPI-triggered activation, most recent data show that
neither membrane insertion nor endocytosis is involved
[42], activation of Toll-like receptor-2 seems to be essential
for induction of TNF by T. cruzi derived GPI [44]. Regard-
ing TNF induction by sVSG, thus far, data are lacking
concerning possible receptor involvement. Incidentally, we
have recently found that though the mannose-6-phosphate
receptor (MPR46) is upregulated during experimental try-
panosome infections, there is no link between the extent of
this event and the occurrence of TNF-mediated pathology
(unpublished data). As such, analysis of the mechanism
involved in GPI-mediated macrophage activation and TNF
production requires further investigation.
5. Vaccination with GPI reduces trypanosomosis-
associated pathology and prolongs survival
Looking back on the discovery of GPI-linked TNF
induction, it is clear that the finding of a phospholipid
containing moiety as part of the TNF-inducing malaria toxin
was a first milestone [45]. However, before that, it had
already been shown that antibodies against exoantigens
from malaria could abrogate their ability to induce TNF
[46], and the idea of an anti-disease vaccination strategy
based upon the generation of anti-TNF-inducing com-
pounds had been proposed as well. The generation of
polyclonal and later monoclonal antibodies with phosphati-
dylinositol specificity that neutralized malaria-triggered
TNF induction further supported this idea [47,48]. More-
over, the initial discovery of infection-induced antibodies in
serum collected in malaria endemic areas that block the
TNF-inducing capacity of malaria toxin [49], and the more
recent confirmation of the anti-GPI nature of these antibod-
ies [50], further substantiate the idea that an anti-disease
vaccination strategy would be a very efficient tool to
attenuate severe GPI-induced pathologies. Finally, the gen-
eration of monoclonal antibodies that block GPI-triggered
signal transduction [39,40], and the finding by Schofield et
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al. (reported at www.BioMedNet.com, News August 2001)
that administration of anti-GPI monoclonal Ab to malaria-
infected mice can abrogate the symptoms of cerebral
malaria and prevent death, give further support for this
possibility. However, despite all these findings, thus far, no
successful active vaccination strategy has been reported that
can actually prevent the occurrence of GPI-induced immu-
nopathology during a parasitic infection. Quite recently, we
have obtained evidence that a VSG-GPI-based vaccination
strategy can indeed prevent TNF-associated immunopathol-
ogy in trypanosome-infected mice (manuscript in prepara-
tion). While cross-protection experiments against various
trypanosome infections as well as cerebral malaria are
ongoing, our results have already indicated the virtual
absence of anemia in VSG-GPI-vaccinated trypanosome-
infected mice. Coinciding with the inhibition of pathology,
we have observed a significant prolongation of survival time
of the infected mice. Since the induced protection was found
to be VSG-type independent, the results indicate that a
GPI-based anti-disease vaccine for trypanosomosis might
be efficacious. Currently, we are investigating in detail the
immunological basis for this protective anti-disease re-
sponse, paying special attention to the regulation of the
activation status of the macrophages involved in VSG-
mediated TNF release. In addition, one point that will have
to be addressed during the functional analysis of this
vaccination strategy is the problem of induction of memory.
Thus far, we have no data on how long a persistent
anti-VSG-GPI memory can be induced, but taking into
account the T-cell-independent nature of anti-malaria toxin
antibodies [46], one might expect only a short-term re-
sponse in laboratory animals. However, in the case of
individuals or animals that are living in an endemic trypa-
nosomosis area, this problem could possibly be overcome
by the regular natural challenge with small doses of VSG-
GPI, even of nonpathogenic T. brucei origin. In fact, this
might then mimic the situation of man in endemic malaria
areas where, as mentioned above, the occurrence of elevated
anti-GPI antibody titers, possibly due to regular natural
challenges, seems to coincide with resistance to clinical
malaria attacks [50].
6. Conclusion
African trypanosomosis is a protozoan parasitic disease
marked by severe immunopathology and systemic inflam-
mation. Due to stimulation by the trypanosome-specific
VSG-GPI anchor, excessive macrophage activation results
in systemic TNF overproduction. A key element in this
process is the repetitive challenge of the immune response
with vast amounts of the galactose-modified VSG-GPI-
carbohydrate core. This cleaved GPI epitope is presented to
the immune system during the successive waves of para-
sitemia, when soluble VSG is released from the parasite
surface by activation of an endogenous PLC enzyme. An
important step in this process, however, is that infection-
associated TNF induction requires a macrophage priming
signal. This is provided by the induction of IFN-γ during the
early stage of infection, and can be enhanced by the
presence of the GPI lipid anchor during later stages of the
infection. As such, both the carbohydrate and the lipid
moieties of the VSG-GPI anchor can play distinct roles in
the final induction of TNF-mediated trypanosomosis-
associated immunopathology. Based on our most recent
results, it is clear that a GPI-based anti-vaccine strategy
might represent an optimal way of preventing infection-
associated immune complications during experimental try-
panosomosis. While under laboratory conditions such a
vaccine does not result in the induction of any direct
anti-trypanosomal activity, it does allow the infected host to
survive with low levels of parasitemia in the absence of
excessive inflammatory responses. As such, once optimized
for field use, this type of vaccine strategy could be a useful
tool in the fight against trypanosomosis, as it would enable
reducing the pathological complications of human sleeping
sickness as well as cutting economic losses due to patho-
logical complications in livestock infections.
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